Natee Meepian / iStockphoto.com
Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bausch Health, Actavis, Teva, Xifaxan, generics, licence, ANDA, settlement, patent infringement, patent settlement